- Home
- NZF vs VCEL Comparison
NZF vs VCEL Comparison
Compare NZF & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NZF | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 2001 | 1996 |
Fundamental Metrics
Financial Performance| Metric | NZF | VCEL |
|---|---|---|
| Price | $10.64 | $40.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.75 |
| AVG Volume (30 Days) | ★ 1.1M | 433.6K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | N/A | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $10.59 | $28.95 |
| 52 Week High | $13.22 | $49.32 |
Technical Indicators
Market Signals| Indicator | NZF | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 18.70 | 48.84 |
| Support Level | N/A | $33.21 |
| Resistance Level | $12.68 | $41.12 |
| Average True Range (ATR) | 0.18 | 1.26 |
| MACD | -0.06 | 0.25 |
| Stochastic Oscillator | 4.36 | 81.62 |
Price Performance
Historical ComparisonAbout NZF Nuveen Municipal Credit Income Fund
Nuveen Municipal Credit Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to enhance portfolio value relative to the municipal bond market by investing in an actively managed portfolio of tax-exempt municipal securities.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.